- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:58 | Celltrion to acquire additional $72 mn in treasury shares | - | Korea Economic Daily | ||
| 03:26 | Celltrion to buy back its shares for 5th time this year | 3 | Korea Herald | ||
| Mi | Celltrion gibt die Übernahme von iQone Healthcare Switzerland bekannt und baut damit seine Expertise und seine Präsenz in Europa weiter aus | 331 | Business Wire | Celltrion gibt die Übernahme von iQone Healthcare Switzerland bekannt und beschleunigt damit die direkte Vermarktung seiner Biosimilars in der europäischen Region Die Übernahme stärkt die... ► Artikel lesen | |
| Di | Celltrion Announces Phase 3 Results of Actemra and Prolia Biosimilars at U.S. Conference | 1 | BusinessKorea | ||
| Fr | Celltrion Acquires Swiss Pharma Distributor iQone | 1 | BusinessKorea | ||
| Fr | Celltrion acquires Swiss pharmaceutical distributor iQone | - | Korea Economic Daily | ||
| Fr | Celltrion Announces the Acquisition of iQone Healthcare Switzerland, Further Building Its Expertise and Foothold in Europe | 326 | Business Wire | Celltrion announces acquisition of iQone Healthcare Switzerland, accelerating direct commercialization of its biosimilars in the European region The acquisition strengthens Celltrion's... ► Artikel lesen | |
| CELLTRION Aktie jetzt für 0€ handeln | |||||
| 08.11. | Celltrion hits record Q3 sales | 2 | Korea Herald | ||
| 08.11. | Celltrion Q3 net profit down 62% to 84.1 bln won | 1 | Yonhap News | ||
| 05.11. | Celltrion releases Steqeyma in Europe | 1 | Korea Economic Daily | ||
| 04.11. | Celltrion expands European reach with anti-imflammatory drug | 1 | Korea Herald | ||
| 30.10. | Celltrion's Zymfentra gets 90% distribution channel in US | - | Korea Economic Daily | ||
| 29.10. | Celltrion's Zymfentra covers over 90% of US health insurance market | 2 | Korea Times | ||
| 29.10. | Celltrion's Zymfentra secures more insurance coverage in U.S. | 1 | Korea Herald | ||
| 29.10. | Celltrion Secures 90% of U.S. Insurance Market for Zymfentra | 1 | BusinessKorea | ||
| 25.10. | Celltrion to buy back its shares for 4th time this year | 4 | Yonhap News | ||
| 22.10. | Celltrion signs $72.8 million deal for migraine drug Ajovy | 2 | Korea Joongang Daily | ||
| 18.10. | Celltrion to form subsidiary for contract development and manufacturing | 2 | Korea Joongang Daily | ||
| 18.10. | Celltrion to establish CDMO subsidiary | - | Korea Economic Daily | ||
| 18.10. | Celltrion to Launch CDMO Subsidiary This Year to Boost Biopharma Capabilities | 1 | BusinessKorea |
Seite:
1 2 3 4 5 Weiter >>
99 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| EVOTEC | 9,915 | +0,10 % | BASF, Evotec, GFT, Knaus Tabbert, LVMH, Wienerberger - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| QUANTUM-SI | 1,400 | 0,00 % | Nvidia Partners With Quantum-Si To Advance Single-Molecule Analysis | ||
| QIAGEN | 39,720 | +2,27 % | Neue 6,00% Aktienanleihe mit Barriere auf QIAGEN in Zeichnung | München (www.anleihencheck.de) - Die Experten vom Zertifikate-Team der Bank Vontobel Europe AG bieten eine neue Aktienanleihe (ISIN DE000VC7RDU1/ WKN VC7RDU) mit Barriere auf die Aktie von QIAGEN (ISIN... ► Artikel lesen | |
| 89BIO | 7,980 | 0,00 % | 89bio, Inc.: 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024 | SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,76 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| RELAY THERAPEUTICS | 4,660 | 0,00 % | Aktie von Relay Therapeutics erreicht 52-Wochen-Tief bei 5,59 US-Dollar | ||
| STRUCTURE THERAPEUTICS | 32,710 | 0,00 % | Structure Therapeutics reports Q3 results | ||
| SPRINGWORKS THERAPEUTICS | 37,440 | 0,00 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| 4D MOLECULAR THERAPEUTICS | 8,410 | 0,00 % | Analyst Expectations For 4D Molecular Therapeutics' Future | ||
| DYNE THERAPEUTICS | 30,000 | 0,00 % | Wissenschaftliche Leiterin von Dyne Therapeutics verkauft Aktien im Wert von 80.539 US-Dollar | ||
| CULLINAN THERAPEUTICS | 12,580 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 6,740 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,550 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen |
CELLTRION INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CELLTRION INC finden Sie auf Wallstreet Online.
